Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Bio-Thera Solutions Has China’s First Adalimumab Biosimilar
Qletli Is Only The Second Biosimilar Approved In China
Nov 13 2019
•
By
David Wallace
China’s NMPA has approved Bio-Thera Solutions’ Adalimumab • Source: Shutterstock
More from Biosimilars
More from Products
